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1. Introduction  
Cytomegalovirus (CMV) end-organ disease is a serious complication after stem cell 
transplantation (SCT) (Boeckh M, 2003). Within the first one hundred days after SCT, 50% of 
recipients develop CMV infection determined by positive antigenemia and 65 to 86.5% 
when viral replication is determined by real-time PCR (RT-PCR) (Ljungman et al., 2006; 
Solano et al., 2001). Described risk factors for CMV infection concern donor type, graft 
source, positive CMV serostatus of donor and recipient, CD34+ graft selection, 
preconditioning regimen, GvHD prophylaxis regimen, incidence of acute and chronic 
GvHD and prophylaxis and treatment for GvHD (Ljungman et al., 2002; Ozdemir et al., 
2007). Pre-emptive therapy is currently based on viral replication determined by either 
antigenemia or RT-PCR (Drew, 2007). Although antigenemia has been extensively used 
(Drew, 2007), RT-PCR has been shown to be more sensitive (Hakki et al., 2003; Solano et al., 
2001). 
The use of techniques based on nucleic acid amplification for the detection of CMV in 
clinical samples are in expansion and in many hospitals have replaced the use of other 
assays such as viral cultures or pp65 antigenemia. Several studies have assessed the 
performance between the different CMV viral load assays available. However, no many 
studies have compared the differences between the DNA extraction methods used (Fahle & 
Fischer, 2000; Caliendo et al., 2007; Kalpoe et al., 2004; Leruez-Ville et al., 2003; Avetisyan et 
al., 2006; Boeckh et al., 2009; Gerna et al., 2008; Gimeno et al., 2008). Although during the 
DNA extraction the majority of the methods use internal controls as a measurement of the 
DNA loss during the extraction procedure, in the downstream amplification not many of the 
assays use DNA standards that will facilitate the comparison among the different kits and 
standardization of the results between hospitals. In fact the availability of an optimal and 
efficient DNA extraction procedure that can use a broad type of samples with minimum 
modifications in the procedure may be practical and affordable for use in the  clinical 
practice (Fahle & Fischer, 2000). 
One of the differences between results using the methods available is type of clinical 
specimen used to perform the CMV DNA extraction. Samples collected vary from plasma, 
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whole blood or leukocytes, with the optimal sample for monitoring CMV viral being 
controversial. Since CMV infect cells, the viral load results obtained from leukocytes 
isolated from peripheral blood or whole blood samples tend to be higher than the results 
obtained from plasma. However, it has been reported a high correlation between CMV 
viral load results from plasma samples and whole blood samples (Caliendo et al., 2007; 
Kalpoe et al., 2004; Leruez-Ville et al., 2003). Moreover, some authors believe that the 
presence of CMV particles in plasma is related with the level of viral replication (Kalpoe 
et al., 2004), representing the infectious viral particles able to spread to other host cells. 
Thus whole blood and plasma samples are equally suitable for testing CMV infection in 
SCT recipients. 
Molecular techniques for CMV quantification such as RT-PCR have been shown to be useful 
for the rapid diagnosis of CMV infection and for monitoring clinical responses to antiviral 
therapy. This technique offers some advantages over others PCR methods, including 
increased precision, accuracy, reproducibility and a shorter turnaround time. To date, the 
clinical utility of using the RT-PCR test to guide preemptive therapy in transplant recipients 
has been mainly studied in SCT recipients (Avetisyan et al., 2006; Boeckh M, 2009; Gerna et 
al., 2008; Gimeno et al., 2008; Harrington et al., 2007; Kalpoe et al., 2004; Lilleri et al., 2004; 
Limaye et al., 2001; Machida et al., 2000; Ruell et al., 2007; Verkruyse et al., 2006). However, 
it has not been established a cutoff threshold for initiating antiviral therapy against CMV 
probably due to the significant differences between the different techniques used to 
determine the CMV viral load. In the absence of standardization the current clinical 
guidelines recommend to each individual laboratory to establish their own viral thresholds 
for CMV management (Kotton et al., 2010; Razonable & Emery, 2004). 
2. DNA extraction methods 
CMV extraction assays can be performed manually and automated. While manual 
extraction assays use non-corrosive reagents, are generally inexpensive and are easy to use, 
they require more labour intensive manipulation increasing the risk for contamination of the 
samples. In addition, this type of extraction procedures requires highly trained laboratory 
personnel to ensure reproducible results. Another limitation of the manual assays is the use 
of ethanol to precipitate the DNA, which may inhibit subsequent RT-PCR assays if not 
properly removed (Valentine-Thon, 2002). The manual assays are mostly used in research 
laboratories where the number of samples used at once is not high and the personnel are 
highly qualified for the procedures.  
Automated extraction methods are not widely extended although there are commonly used 
in clinical services where the number of clinical samples to process every day is high. The 
main feature of the automated extraction systems is the increase in reproducibility of the 
extraction among different samples, in addition to a reduction of the risk of contamination 
and the high number of samples that could be performed at the same time. However, the 
main handicap of this technology is the elevated cost of the instruments, as well as the high-
costs of instruments` reagents and maintenance and the necessary laboratory space required 
(Espy et al., 2006). 
While recently reports have shown improvement in the sensibility obtained by the 
automated extraction instruments in comparison with the manual extraction kits (Gartner 
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et al., 2004; Mengelle et al., 2011), and several studies performed on different 
herpesviruses have shown increased sensibility when automated extraction was 
performed compared to manual extraction kits (Nicholson et al.; 1997; Griffiths et al.; 
1984), our laboratory recently demonstrated that the DNA extraction method from 
Affigene was more efficient than the automated system from Abbott  providing a more 
accurate estimation of CMV DNA load (Gracia-Ahufinger et al., 2010). Our data proving 
that the manual DNA extraction method from Affigene resulted in a more efficient DNA 
extraction in comparison with that of an automated procedure from Abbott were 
somewhat surprising and are in contrast to previously published studies showing just the 
opposite (Kalpoe et al., 2004; Limaye et al., 2001). In this context, our data underscore the 
fact that the DNA extraction efficiency of distinct automated systems may not be 
comparable and should be thoroughly evaluated. This finding translates into critical 
therapeutic consequences, as patients would be treated depending on a threshold viral 
load, which will be different depending on the method used. In this context, these data 
reinforce the idea that local guidelines for the initiation of pre-emptive therapy based on 
commercial assays must be established as long as universally accepted standards for 
quantitative analysis of CMV DNAemia are not available. 
3. Detection of CMV infection  
CMV viral load determination is used to diagnose active CMV infection, to adopt treatment 
strategies to prevent CMV infection after transplantation and to monitor CMV after therapy. 
For this reason it is necessary to establish robust and reproducible assays to make possible 
to detect CMV levels within a wide range from low to very high number of copies (Abbate 
et al., 2008). 
3.1 CMV detection using antigemia assays  
The pp65 antigenemia developed in the late 1980s was the first non-cell culture based 
quantitative assay used in clinic to detect CMV infection (Atkinson & Emery), making 
obsolete the previous techniques such as shell vial assays (Gleaves et al., 1984; Nicholson 
et al., 1997), or the detection of early antigen fluorescent foci (DEAFF) test (Griffiths et al., 
1984). The pp65 antigenemia assay is based on the detection of the pp65 phosphoprotein 
of CMV in peripheral blood leukocytes (Van der Bij et al., 1988), and it has been widely 
used for years to quantify and guiding the administration of therapy and monitoring 
active CMV infection of STC recipients (Bonon et al., 2005; Tormo et al., 2010). However, 
the antigenemia assay has many disadvantages such as, it requires quite a lot blood 
volume as well as intensive labour and need to process samples within 6h from the time 
of collection to achieve optimal sensitivity (Kim et al., 2007; Mhiri et al., 2007), it restricts 
the numbers of samples that can be analyzed simultaneously and it requires a high 
number of leukocytes (at least more than 200 leukocytes) for acceptable performance of 
the assay (Preiser et al., 2001), being unfeasible during periods of severe neutropenia. In 
addition, due to the fact that antigenemia results can be elevated after following 
ganciclovir treatment despite of a decrease of DNAemia levels, results using antigenemia 
for monitoring efficacy of the pre-emptive therapy of CMV infection in SCT recipients 
may be mislead (Sia et al., 2000). Other molecular techniques have reduced the 
turnaround time for monitoring CMV infection.  
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3.2 Qualitative PCR assays  
In the past few years new sensitive PCR based techniques have been developed for earlier 
detection of CMV infection. The new assays developed were initially qualitative and they 
were able to detect CMV viremia in plasma of SCT recipients, and were compared with 
antigenemia assay (Boeckh et al., 1997; Boivin et al., 2000; Ksouri et al., 2007; Mori et al., 
2000; Preiser et al., 2001). Results from Boivin et al. found a higher sensitivity in antigenemia 
test, while Boeckh et al. suggested a similar sensibility in both techniques. Most of these 
studies used in-house PCR assays (Boeckh et al., 1997; Boivin et al., 2000; Preiser et al., 2001), 
which made difficult to compare results and to conclude the clinical value of the methods 
(Solano et al., 2001). 
The AMPLICOR CMV DNA PCR assay (Roche Diagnostics, Branchburg, N.J.) was the first 
qualitative technique commercialized. However, despite of being a more sensitive 
technique, antigenemia was found to be a more suitable technique both for guiding the 
initiation of preemptive therapy and for monitoring the efficacy of ganciclovir treatment 
(Solano et al., 2001).  
3.3 Quantitative PCR assays  
The quantitative PCR assays have demonstrated to be more suitable and clinically 
relevant than qualitative PCR for the detection of CMV DNA (Sia et al., 2000), providing 
useful information for the management of patients at high risk for developing CMV 
infection. Quantitative results may facilitate the establishment of a threshold for CMV 
viral load and the discrimination between patients who had symptomatic CMV infection 
and those who do not. Thus, allowing to establish the degree of viral replication and to 
distinguish between low and high level of CMV infection that may lead to disease after 
SCT (Preiser et al., 2001). Although there are many different commercially available 
quantitative PCR assays for CMV detection, the COBAS AMPLICOR CMV MONITOR test 
is one of the more commonly used in the clinical practice. This quantitative PCR 
developed by Roche included an internal quantification standard. The performance of the 
assay was found to be more sensitive compared with other qualitative tests (Boivin et al., 
2000; Caliendo et al., 2001), with a lower limit of detection of 400 copies/ml of plasma and 
a dynamic range up to 50,000CMV DNA copies/ml. This assay has been widely used for 
early detection of CMV infection in a variety of clinical specimens and clinical studies 
(Ghisetti et al., 2004; Lehto et al., 2005; Martin-Davila et al., 2005; Piiparinen et al., 2005; 
Sia et al., 2000; Westall et al., 2004). However, it shows some disadvantages, due to the 
fact that it requires manual extraction it has a low number of sample processing (24 per 
run) and a long performance (approximately 8 h).  In addition, the limit of detection has 
been established in 2.78 log10 cop/ml, value that is high especially for the early detection 
of CMV replication (Kerschner et al., 2011). 
The use of quantitative PCR to detect CMV infection has been highly controversial 
regarding the specimen used (plasma, whole blood or leukocytes) for the quantification 
of the CMV viral load (Boeckh et al., 1997; Boivin et al., 2000; Caliendo et al., 2000; 
Flexman et al., 2001; Kaiser et al., 2002; Machida et al., 2000; Razonable et al., 2002; 
Tanaka et al., 2000; Weinberg, Schissel, & Giller, 2002). Some studies have suggested that 
quantitative PCR measurements for monitoring CMV viral load in whole-blood have a 
www.intechopen.com
 Detection of CMV Infection in Allogeneic SCT Recipients: The Multiple Assays 
 
411 
higher sensitivity compared to using cells or plasma during CMV disease in 
immunocompromised patients (Razonable et al., 2002) (von Muller et al., 2007). The 
authors consider that whole blood includes all the compartments in which the virus can 
replicate (Deback et al., 2007). In addition, Cortez et al found that quantitative PCR 
performed in whole blood provided a higher number of positive results (58.2% vs. 
39.5%) compared to plasma (Cortez et al., 2003). However, Leruez-Ville et al. compared 
the performance of a RT-PCR specifically to amplify high conserved region of CMV 
UL93 gene in plasma and whole blood, demonstrating that both plasma and whole  
blood were equally suitable for monitoring active CMV infection (Leruez-Ville et al., 
2003).  
3.4 RT-PCR assays 
In the mid 1990s become available the first two commercialized RT-PCR platforms. In the 
last years, different companies have tried to improve the technique including faster 
cycling, higher throughput and flexibility, new optical systems and more accessible 
software (Table 1). For example, it has been developed several versions of the LightCycler 
instruments such as Roche LightCycler™ PCR or SmartCycler (Cepheid) for performing 
sensitive, specific and rapid assays for the detection of CMV, time- and cost-effectiveness 
and with low contamination risk (Schaade et al., 2000). RT-PCR based on TaqMan probes 
and related technologies have proven higher dynamic range, precision, accuracy, 
reproducibility, a shorter turnaround time and a low risk of contamination, offering many 
advantages over quantitative-competitive PCR assays. With the use of these techniques, 
the quantification of CMV in clinically relevant samples could be reproducibly achieved 
in 2h allowing to understand CMV replication kinetics in humans (Atkinson & Emery, 
2011). In addition, other advantages have been described about the use of RT-PCR to 
evaluate the CMV load in HSCT including the ability to test blood during episodes of 
neutropenia and subsequent disease that had been missed by antigenemia (Kaiser et al., 
2002). 
On the contrary, RT-PCR also has some disadvantages compared with conventional PCR 
such as the start-up expense of the assay and the incompatibility of some platforms with 
certain reagents (Mackay, Arden, & Nitsche, 2002). 
Although most of RT-PCR assays for monitoring CMV infection in SCT recipients have 
been laboratory developed (Boeckh et al., 2004; Griscelli et al., 2001; Herrmann et al., 
2004; Hong et al., 2004; Kalpoe et al., 2004; Leruez-Ville et al., 2003; Lilleri et al., 2004; 
Limaye et al., 2001; Nitsche et al., 2000; Pumannova et al., 2006; Ruell et al., 2007; 
Schaade et al., 2000; Tanaka et al., 2000; Tanaka et al., 2002; Yakushiji et al., 2002; Yun et 
al., 2003), several commercial tests are available and have been used in different clinical 
diagnostic laboratories. However, there are not many studies based on the application of 
these commercial assays in SCT recipients (Bravo et al.; Gimeno et al., 2008; Gouarin et 
al., 2007; Gracia-Ahufinger et al., 2010; Hanson et al., 2007). As it will be described 
below, these studies evaluated the suitability of the commercial assays for the 
surveillance of active CMV infection in these patients and compared the performance of 
the different tests.  
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
412 
LABORATORY DEVELOPED REAL TIME PCR 
ADVANTAGES REF 
Less expensive and with the possibility of being 
personally established by developers. 
[10, 11, 17, 18, 20, 56, 61, 63-71] 
COMMERCIAL REAL TIME PCR 
NAME MANUFACTURER 
VIRAL 
TARGET 
ADVANTAGES REF 
COBAS 
Amplicor CMV 
Monitor 
Roche UL54 
Sensitive, low limit of 
detection and broad 
dynamic range. 
[40-45, 
51] 
LightCycler® 
CMV 
Quantitative Kit 
Roche UL54 
Reasonably accurate, 
sensitive, specific and 
linear. Suitable for the 
detection of CMV DNA 
early after 
transplantation. 
[74,75] 
Artus CMV  
PCR test 
QIAGEN UL122 
Reliable CMV 
diagnostic early after 
transplantation. 
High sensitivity and 
performance. 
74 
CMV R-geneTM Argene UL83 
Accurate quantification 
in SCT patients, good 
correlation with other 
RT-PCR assays and 
pp65 antigenemia. 
Validated with several 
types of specimen and 
DNA purification 
systems (automatic and 
manual). 
73 
Abbott CMV 
real-time PCR 
Kit 
Abbott Diagnosis UL122 
High sensitivity and 
very low limit of 
detection (25 cps/mL). 
Good correlation with 
antigenemia and 
suitable to monitoring 
active CMV infection in 
SCT patients. 
[15, 72] 
Affigene CMV 
Trender 
Cepheid Not specified 
Robust, reproducible 
and sensitive. Better 
analytical performance 
than the Abbot test and 
accurate estimation of 
the viral load. 
[29,28] 
Table 1. Technical advantages of the laboratory developed and commercially available RT-
PCR methods. 
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3.4.1 Commercial RT-PCR assays  
There are several commercially available RT-PCR assays developed for the detection of 
CMV infection in clinical samples. Most of these assays use specific targets, such as UL83, 
UL123 genes or the HXFL4 region (Alain et al.; Caliendo et al., 2007; Gault et al., 2001; 
Gouarin et al., 2007; Mengelle et al., 2003). The most common targets used for the detection 
of CMV by RT-PCR are the immediate early (IE) gene (Nitsche et al., 1999), the polymerase 
(UL54) gene (Schaade et al., 2000) , the glycoprotein B gene (UL55) (Espy et al., 2006) and the 
pp65 gene (UL83)  (Stocher et al., 2003). Among the commercially available standardized 
methods to detect CMV infection, the LightCycler® CMV Quantitative Kit (Roche), the 
RealArt CMV LightCycler PCR reagent test (QIAGEN, Germantown, MD), CMV R-geneTM 
(Argene, France), Affigene CMV Trender (Cepheid, Sweden) and the Abbott CMV real-time 
PCR Kit (Abbott Diagnosis, USA) have been evaluated in SCT. 
The LightCycler® CMV Quantitative assay (Roche) is a standardized RT-PCR test based on 
analyte-specific reagents (ASR) designed to detect a fragment of 240 pb within the 
polymerase gene (UL54) (Alain et al.). This test has been compared with the RealArt CMV 
LightCycler PCR reagent test (QIAGEN) that detects a fragment of 105 pb within the IE gene 
(Hanson et al., 2007).  They made the comparison using OptiQuant CMV DNA panels 
(AcroMetrix Corp.) that contained four concentrations of CMV strain AD169 and with 
plasma specimens collected from SCT recipients. Although both tests were suitable to detect 
CMV DNA early after transplantation, the results using the Qiagen test showed higher 
sensitivity as well as a better performance at the lower standard concentration (Hanson et 
al., 2007). 
Other remarkable CMV RT-PCR assay is the CMV R-geneTM (Argene, France) that targets 
the pp65 gene (UL83). This test has been evaluated in SCT recipients from four centers 
showing an accurate quantification, as well as a good correlation with other laboratory-
developed RT-PCR assays and pp65 antigenemia, thus the authors suggest that the R-gene 
test is a good alternative method to diagnose and monitor CMV infection (Gouarin et al., 
2007). The Affigene CMV Trender kit was developed by Cepheid and it has been shown to 
be robust, reproducible and sensitive enough for routine measurement of patient samples 
(Abbate et al., 2008). The analytical performance of this assay was also evaluated in our 
laboratory compared with the Abbott CMV RT-PCR Kit, using samples obtained from SCT 
recipients. The Affigene CMV Trender assay yielded higher viral load than the Abbot test, 
suggesting a better analytical performance. The comparison was also performed using the 
OptiQuant CMV DNA quantification panel showing that the Affigene test provides a more 
accurate estimation of the CMV DNA load (Gracia-Ahufinger et al., 2010). The test 
manufactured by Abbott, was previously evaluated in plasma samples from SCT recipients 
(Gimeno et al., 2008).  
However the assay was compared with the antigenemia test to monitoring active CMV 
infection in SCT patients. Results showed a good correlation of the results but higher 
sensitivity for the RT-PCR assay (Gimeno et al., 2008). More recently the Abbott CMV RT-
PCR assay was also evaluated in SCT recipients compared with other two commercial tests 
(Roche and Nanogen) (Bravo et al., 2011). The results found variations in the performance of 
the tests which limited to establish a common cutoff between different assays. This issue 
will be discussed below. 
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4. CMV viral load threshold for treatment initiation 
The development of antiviral strategies has resulted in a large decrease in the incidence of 
CMV disease. Two main therapeutic strategies have been developed for the control of CMV 
infection and prevention of CMV disease, prophylaxis and pre-emptive therapy. Both 
strategies have been shown to be equally effective to protect against CMV infection. In the 
prophylaxis strategy antiviral treatment is administered to all patients after transplantation 
for a period of time between 100 and 200 days. (Boeckh M, 2003; Hebart & Einsele, 2004; 
Meijer et al., 2003; Zaia, 2002). In the pre-emptive strategy treatment is administered only 
when the CMV viral load reaches an established threshold (Gimeno et al., 2008; Machida et 
al., 2000). The preemptive administration of treatment consequently requires the use of 
highly sensitive assay for monitoring CMV viral load.  
The International Consensus Guidelines on the Management of CMV after transplantation 
considered necessary the establishment of a universal cut-off value for initiating therapy 
(Razonable & Emery, 2004). Several studies have tried to establish the clinical utility of using 
the RT-PCR test to guide preemptive therapy in SCT recipients (Avetisyan et al., 2006; 
Boeckh M, 2009; Gerna et al., 2008; Gimeno et al., 2008; Harrington et al., 2007; Kalpoe et al., 
2004; Lilleri et al., 2004; Limaye et al., 2001; Machida et al., 2000; Ruell et al., 2007; Verkruyse 
et al., 2006). However as stated earlier, there are significant differences between the different 
techniques used to determine the CMV viral load, thus the standardization of specific cutoff 
values is limited by the variations in the performance of the test, the assay design, and the 
diversity in the patient population studied thus results can not be extrapolated. So, it would 
be necessary an international reference standard between viral loads obtained with different 
tests. Currently, each laboratory must establish its own cutoff value and monitor clinical 
outcomes to verify the trigger points used. 
Some authors have suggested that pre-emptive therapy should be initiated after two 
consecutive increased viral load values (Boeckh M, 2009; Gimeno et al., 2008). However, the 
inter- and intra-assay variability in some cases with variations over 30% that may represent 
a risk for using this treatment initiation strategy (Boeckh & Boivin, 1998; Boeckh & Nichols, 
2004), with variations of the viral load less than 0.5 log may not be significant. Other authors 
propose considering CMV replication kinetics for the initiation of treatment. In these cases, 
it needs to be considered that while CMV duplicate within 1-2 days on average, the time for 
replication is shorter in the presence of immunosuppressant drugs, which may result in 
faster increase of the viral loads. In addition in these cases may be necessary taking into 
account the initial viral load since it is predictive of risk for developing CMV disease (Emery 
& Griffiths, 2000). 
Some studies have established optimal cut-offs for treatment initiation, classifying patients 
according to the risk for developing CMV disease. A recent publication by Boeckh and 
Ljungman recommends initiating treatment with viral loads over 100 copies/ml in SCT 
recipients at high risk for CMV infection that received the transplant within the last 100 
days, and 500 copies/ml for patients at low risk. For long-term SCT recipients initiation of 
treatment is recommended with viral loads over 1,000 copies/ml (Boeckh M, 2009).  
Most of the studies to establish thresholds for the control of CMV infection have been 
performed using plasma for testing CMV viral load with a wide range of cut-off viral loads 
varying from 550 copies/ml to 10,000 copies/ml (Avetisyan et al., 2006; Gimeno et al., 2008; 
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Hong et al., 2004; Yakushiji et al., 2002). Other studies have established thresholds for the 
control of CMV infection of 1,000 copies/ml (Boeckh M, 2009; Harrington et al., 2007), and 
10,000 (Gerna et al., 2008; Lilleri et al., 2004; Verkruyse et al., 2006) using whole blood. These 
cut-off values were defined to be protective independently of their CMV sero-status. Few 
studies have established a protective cut-off for CMV infection in leukocytes; one of these 
established a cut off of 1,000 CMV genomes copies per 200,000 leukocytes (Avetisyan et al., 
2006).  
Another important issue after transplantation is the optimal frequency of CMV monitoring 
which has not been defined for SCT. Most authors recommend a weekly periodicity 
increased twice a week once CMV replication is detected and during treatment 
administration, while treatment administration should be interrupted after two consecutive 
negative determinations (Boeckh M, 2009). 
In summary, it has not been established a cutoff threshold for initiating antiviral therapy 
against CMV maybe due to differences in CMV serological status, immunosuppressive drug 
regimens and period of treatment. Further studies are necessary in large series of SCT 
recipients assessing safety of viral load thresholds. 
5. Standardization of CMV viral load quantification 
Since CMV viral loads (in copies per milliliter of body fluid) correlate with the 
development of CMV disease (Emery & Griffiths, 2000; Humar et al., 1999), the use of 
molecular diagnostics based on the measurement of the viral load has contributed to 
patients’ management after transplantation for more than a decade. During preemptive 
administration of treatment, antiviral therapy is initiated when CMV replication reaches 
an established threshold in the peripheral blood (Lilleri et al., 2009), prior to develop 
clinical symptoms. Therefore, the use methods such as RT-PCR can be useful to 
determine when to initiate the preemptive therapy and its duration (Emery & Griffiths, 
2000; Humar et al., 1999; Humar et al., 2002; Sia & Patel, 2000) as well as to monitor the 
response to the administered therapy. However, as previously stated the most important 
handicap of the available RT-PCR techniques is the high variability of CMV viral load 
results among different laboratories. Pang et al designed a comparative study among 
thirty laboratories to evaluate the reproducibility of in-house and commercial assays to 
detect CMV infection. They prepared a panel of samples with different CMV DNA 
concentrations that were evaluated in different laboratories, with several commercial 
available assays. While the intra-laboratory coefficient of variation was considered 
acceptable (around 17%), they inter-laboratory variability resulted higher than 140%. 
These authors considered that differences in viral load lower at <0.5 log10 are not 
considered clinically relevant. This difference limits the comparisons inter-laboratories 
and prevents the establishment of a determinate cut-off broadly applicable for making 
clinical decisions and monitoring the initiation of pre-emptive therapy (Caliendo et al., 
2009). These discrepancies result into clinical therapeutic consequences, as a number of 
patients  may receive treatment in one hospital while not in other hospital using a 
different assay (Gracia-Ahufinger et al., 2010).  
The differences among assays are based on the method for nucleic acid extraction, the 
specimen type, the target genomic region, primers and probes used for amplification and 
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detection (Caliendo et al., 2009; Ikewaki et al., 2005). Although, the variability in the results 
obtained with commercial assays (kits or ASRs) are proven to be lower than when using in-
house developed methods (Pang et al., 2009).  
The most critical factor for standardization is the lack of using an universally accepted 
standard for CMV quantification will make possible the comparison among results thus 
establishing a common management of patients in different centers (Atkinson & Emery, 
2011). The reference material used as a calibrator have to be traceable and commutable to 
achieve accurate clinical results ensuring consistency with clinical samples (Caliendo et al., 
2009). While many laboratories produce their own calibrator as an attempt of standardizing 
some CMV reference material is under development and in fact there are standards 
commercially available for quantification. For instance, the National Institute of Standards 
and Technology (NIST) started the development of a reference standard for CMV based on 
pure CMV DNA from a Towne strain from which after some modification, the final 
construct will be used to produce viral DNA (Wang et al., 2004). Moreover, the OptiQuant® 
CMV DNA Quantification Panel from AcroMetrix has been carefully formulated to mimic 
naturally occurring human specimens containing CMV viral DNA. It consists of cultured 
CMV that has been diluted in defibrinated, delipidized normal human plasma at different 
concentrations. The panel can be used with any test procedure designed for measuring CMV 
DNA in human serum or plasma and it has been widely used as a standard in several 
studies (Bravo et al.; Forman et al., 2011; Hanson et al., 2007; Raggam et al., 2010) to compare 
techniques with the same laboratory and inter-laboratory.  
In the absence of standardization the current clinical guidelines recommend to each 
individual laboratory to establish their own viral thresholds for CMV management, (Kotton 
et al., 2010; Razonable & Emery, 2004), threshold that cover a wide range of viral loads 
varying from 200-500 copies/mL in some laboratories (Ikewaki et al., 2005; Mori et al., 2002) 
to 2000-5000 copies/mL in others (Humar et al., 1999). 
6. Conclusions 
In conclusion, the quantitative PCR assays have demonstrated to be more suitable and 
clinically relevant for the monitoring of the CMV viral load, and the management of patients 
that develop CMV infection. Although there are several commercially available RT-PCR 
assays developed for the detection of CMV infection in clinical samples, there are variations 
in the performance of these tests which limit to establish a common cutoff between different 
assays. Each laboratory must establish its own cutoff value and monitor clinical outcomes to 
verify the trigger points used. Using universally accepted standards for CMV quantification 
will make possible the comparison among results establishing a common management of 
patients in different centers. However, in the absence of standardization the current clinical 
guidelines recommend to each individual laboratory to establish their own viral thresholds 
for CMV management. Further studies are still necessary to establish standardized cut-off 
values in large series of transplant recipients. 
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